Complete Filing Data
Alector, Inc. reported Stockholders Equity of $30.65 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Alector, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$142.9M | -$119.0M | -$130.4M | -$133.3M | -$36.3M | -$190.2M | -$105.4M | -$52.2M | -$32.5M |
| Revenue * | $21.0M | $100.6M | $97.1M | $133.6M | $207.1M | $21.1M | $21.2M | $27.5M | $2.9M |
| Operating Income Loss | -$156.0M | -$145.0M | -$151.7M | -$137.8M | -$37.4M | -$195.2M | -$114.4M | -$57.3M | -$32.7M |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -$95.0K | $77.0K | $4.8M | -$3.6M | -$1.6M | $472.0K | $184.0K | -$42.0K | |
| Research And Development Expense | $123.1M | $185.9M | $192.1M | $210.4M | $189.4M | $156.9M | $100.5M | $73.0M | $29.9M |
| Other Nonoperating Income Expense | $13.2M | $26.1M | $26.6M | $7.8M | $1.0M | $4.9M | $9.0M | $5.0M | $199.0K |
| Operating Expenses | $177.1M | $245.6M | $248.8M | $271.5M | $244.4M | $216.3M | $135.6M | $85.0M | $36.4M |
| General And Administrative Expense | $54.0M | $59.6M | $56.7M | $61.0M | $55.0M | $59.4M | $35.1M | $11.9M | $6.5M |
| Comprehensive Income Net Of Tax | -$143.0M | -$119.0M | -$125.6M | -$136.9M | -$37.9M | -$189.8M | -$105.2M | -$52.3M | -$32.5M |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax | -$95.0K | $77.0K | $4.8M | -$3.6M | -$1.6M | $472.0K | $184.0K | -$42.0K | |
| Income Tax Expense Benefit | $168.0K | $128.0K | $5.2M | $3.3M | $0.00 | $0.00 | |||
| Income Loss From Continuing Operations Before Income Taxes Domestic | -$142.8M | -$118.9M | -$125.2M | -$130.1M | -$36.3M | -$190.2M | |||
| Operating Lease Impairment Loss | $2.9M | $2.2M | $0.00 | $0.00 | $0.00 | $238.0K | $1.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 | Q2 2019 | Q1 2019 | Q4 2018 | Q3 2018 | Q2 2018 | Q1 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$34.7M | -$30.5M | -$40.5M | -$42.2M | -$38.7M | -$36.1M | -$44.5M | $1.4M | -$45.9M | -$46.1M | $9.9M | -$44.6M | $126.6M | -$55.1M | -$52.2M | -$52.7M | -$45.3M | -$40.0M | -$30.5M | -$31.7M | -$24.6M | -$18.6M | -$17.4M | -$15.3M | -$11.1M | -$8.4M |
| Revenue * | $3.3M | $7.9M | $3.7M | $15.3M | $15.1M | $15.9M | $9.1M | $56.2M | $16.5M | $14.9M | $79.9M | $24.5M | $182.4M | $6.6M | $4.1M | $5.9M | $3.2M | $7.2M | $6.0M | $2.7M | $6.9M | $5.6M | $9.1M | $6.5M | $7.1M | $4.8M |
| Operating Income Loss | -$37.6M | -$34.1M | -$44.7M | -$48.4M | -$45.6M | -$43.7M | -$50.6M | -$3.6M | -$50.1M | -$47.7M | $9.5M | -$44.1M | $126.3M | -$55.3M | -$52.6M | -$53.7M | -$46.6M | -$42.1M | -$32.3M | -$34.1M | -$27.2M | -$20.8M | -$19.0M | -$16.8M | -$12.2M | -$9.2M |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $101.0K | -$95.0K | -$70.0K | $1.6M | -$217.0K | -$587.0K | $665.0K | $813.0K | $2.4M | -$518.0K | -$2.3M | -$3.0M | -$244.0K | -$207.0K | -$204.0K | -$752.0K | -$936.0K | $2.6M | -$215.0K | $333.0K | $150.0K | -$48.0K | $62.0K | -$154.0K | ||
| Research And Development Expense | $29.4M | $27.6M | $33.6M | $48.0M | $46.3M | $45.2M | $46.3M | $46.2M | $51.9M | $48.3M | $54.5M | $53.0M | $43.1M | $47.8M | $45.7M | $43.8M | $34.1M | $34.6M | $28.5M | $25.6M | $20.6M | $20.4M | $16.8M | $11.7M | ||
| Other Nonoperating Income Expense | $2.9M | $3.6M | $4.2M | $6.2M | $7.0M | $7.6M | $7.4M | $6.4M | $5.2M | $2.3M | $1.5M | $264.0K | $268.0K | $178.0K | $464.0K | $1.0M | $1.3M | $2.1M | $2.4M | $2.6M | $2.2M | $1.5M | $1.1M | $788.0K | ||
| Operating Expenses | $40.9M | $42.0M | $48.4M | $63.8M | $60.7M | $59.6M | $59.7M | $59.8M | $66.7M | $62.6M | $70.4M | $68.6M | $56.1M | $61.9M | $56.7M | $59.7M | $49.8M | $49.2M | $36.8M | $34.1M | $26.4M | $23.3M | $19.3M | $14.1M | ||
| General And Administrative Expense | $11.5M | $14.4M | $14.7M | $15.8M | $14.4M | $14.4M | $13.4M | $13.6M | $14.8M | $14.3M | $15.8M | $15.6M | $13.0M | $14.1M | $11.0M | $15.8M | $15.7M | $14.6M | $8.3M | $8.4M | $5.8M | $2.9M | $2.5M | $2.4M | ||
| Comprehensive Income Net Of Tax | -$34.6M | -$30.6M | -$40.5M | -$40.7M | -$38.9M | -$36.7M | -$43.8M | $2.2M | -$43.5M | -$46.7M | $7.6M | -$47.6M | $126.4M | -$55.4M | -$52.4M | -$53.5M | -$46.3M | -$37.4M | -$32.0M | -$24.2M | -$18.4M | -$15.4M | -$11.1M | -$8.6M | ||
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax | $101.0K | -$95.0K | -$70.0K | $1.6M | -$217.0K | -$587.0K | $665.0K | $813.0K | $2.4M | -$518.0K | -$2.3M | -$3.0M | -$244.0K | -$207.0K | -$204.0K | -$752.0K | -$936.0K | $2.6M | -$215.0K | $333.0K | $150.0K | -$48.0K | $62.0K | -$154.0K | ||
| Income Tax Expense Benefit | $0.00 | $0.00 | $0.00 | $0.00 | $73.0K | $7.0K | $1.3M | $1.4M | $901.0K | $733.0K | $1.0M | $758.0K | $0.00 | $0.00 | $0.00 | |||||||||||
| Income Loss From Continuing Operations Before Income Taxes Domestic | -$34.7M | -$30.5M | -$40.5M | -$42.2M | -$38.6M | -$36.1M | -$43.2M | $2.8M | -$45.0M | -$45.4M | $10.9M | -$43.9M | $126.6M | -$55.1M | -$52.2M | |||||||||||
| Operating Lease Impairment Loss |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $30.6M | $126.8M | $134.2M | $214.4M | $300.7M | $267.5M | $194.7M | -$97.4M | -$52.0M | -$24.9M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $67.6M | $34.9M | $76.1M | $155.8M | $330.6M | $51.4M | $91.1M | $66.9M | $32.5M | $51.0M |
| Restricted Cash Noncurrent | $1.8M | $1.8M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | ||
| Cash And Cash Equivalents At Carrying Value | $65.8M | $33.0M | $74.6M | $154.3M | $329.2M | $50.0M | $89.6M | $65.5M | $32.5M | |
| Accretion Amortization Of Discounts And Premiums Investments | $6.6M | $14.4M | $15.3M | $1.2M | -$2.1M | -$584.0K | $4.7M | $2.7M | ||
| Retained Earnings Accumulated Deficit | -$972.1M | -$829.1M | -$710.1M | -$579.7M | -$446.4M | -$410.0M | -$219.8M | -$114.4M | ||
| Property Plant And Equipment Net | $10.8M | $17.1M | $21.9M | $25.5M | $27.3M | $30.2M | $33.9M | $10.9M | ||
| Prepaid Expense And Other Assets Current | $10.4M | $11.4M | $16.9M | $11.0M | $7.1M | $8.2M | $4.4M | $2.8M | ||
| Other Liabilities Noncurrent | $1.7M | $1.2M | $1.4M | $759.0K | $158.0K | $472.0K | $493.0K | $96.0K | ||
| Other Assets Noncurrent | $386.0K | $4.5M | $7.4M | $6.4M | $5.6M | $2.6M | $676.0K | $2.8M | ||
| Liabilities Current | $69.5M | $125.1M | $177.9M | $93.8M | $139.6M | $68.1M | $62.0M | $47.9M | ||
| Liabilities And Stockholders Equity | $293.2M | $468.3M | $621.8M | $787.6M | $814.7M | $488.3M | $421.9M | $308.4M | ||
| Liabilities | $262.6M | $341.5M | $487.7M | $573.2M | $513.9M | $220.7M | $227.2M | $195.2M | ||
| Contract With Customer Liability Noncurrent | $164.5M | $172.2M | $210.8M | $443.4M | $334.4M | $108.4M | $123.2M | $139.7M | ||
| Contract With Customer Liability Current | $6.7M | $23.7M | $83.0M | $48.2M | $90.8M | $23.9M | $30.2M | $34.9M | ||
| Common Stock Value | $11.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | $1.0K | ||
| Assets Current | $266.5M | $424.8M | $565.8M | $726.4M | $749.7M | $421.5M | $357.4M | $293.2M | ||
| Assets | $293.2M | $468.3M | $621.8M | $787.6M | $814.7M | $488.3M | $421.9M | $308.4M | ||
| Accrued Liabilities Current | $19.3M | $28.9M | $30.4M | $27.8M | $27.5M | $22.5M | $18.3M | $8.4M | ||
| Accrued Clinical Supply Cost | $3.7M | $7.0M | $5.2M | $5.6M | $8.7M | $11.1M | $6.7M | $4.5M | ||
| Accounts Payable Current | $1.7M | $2.2M | $3.8M | $4.2M | $4.7M | $3.0M | $278.0K | $126.0K | ||
| Marketable Securities Current | $190.2M | $380.4M | $474.3M | $558.5M | $406.1M | $363.3M | $263.4M | $224.9M | ||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $166.0K | $261.0K | $184.0K | -$4.6M | -$943.0K | $614.0K | $142.0K | -$42.0K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $32.8M | -$41.2M | -$79.7M | -$174.8M | $279.2M | -$39.7M | $24.2M | $34.5M | -$18.6M | |
| Operating Lease Right Of Use Asset | $13.7M | $20.0M | $25.2M | $27.8M | $30.6M | $32.5M | $28.5M | $31.4M | ||
| Operating Lease Liability Noncurrent | $17.5M | $24.4M | $30.5M | $35.3M | $39.8M | $43.7M | $41.5M | |||
| Operating Lease Liability Current | $9.1M | $8.8M | $8.5M | $8.1M | $7.8M | $7.5M | $6.6M | |||
| Gain Loss On Sale Of Property Plant Equipment | $0.00 | $0.00 | -$107.0K | $39.0K | -$151.0K | |||||
| Issuance Costs Of Common Stock | $408.0K | $3.9M | $1.1M | $3.9M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q3 2018 | Q2 2018 | Q1 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $57.7M | $71.2M | $94.6M | $118.9M | $150.6M | $178.9M | $162.6M | $196.3M | $183.0M | $253.1M | $288.5M | $267.5M | $335.9M | $184.5M | $227.8M | $310.2M | $355.3M | $391.7M | $218.6M | $245.7M | $266.2M | -$82.8M | -$69.4M | -$59.5M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $78.3M | $46.6M | $39.8M | $38.7M | $49.1M | $74.1M | $103.5M | $133.1M | $197.0M | $185.7M | $173.7M | $456.1M | $518.0M | $127.2M | $112.2M | $86.5M | $94.0M | $162.4M | $88.4M | $70.7M | $62.4M | $43.4M | $50.4M | $37.4M |
| Restricted Cash Noncurrent | $1.8M | $1.8M | $1.8M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | ||
| Cash And Cash Equivalents At Carrying Value | $76.5M | $44.8M | $38.0M | $37.2M | $47.5M | $72.6M | $102.0M | $131.5M | $195.6M | $184.2M | $172.3M | $454.6M | $516.5M | $125.7M | $110.7M | $85.0M | $92.5M | $160.9M | $87.0M | $69.2M | $61.0M | $41.9M | $48.9M | $37.4M |
| Accretion Amortization Of Discounts And Premiums Investments | $2.0M | $4.6M | $2.6M | -$570.0K | -$594.0K | $240.0K | $1.3M | $352.0K | ||||||||||||||||
| Retained Earnings Accumulated Deficit | -$934.8M | -$900.1M | -$869.6M | -$827.1M | -$784.8M | -$746.2M | -$668.6M | -$624.2M | -$625.5M | -$527.3M | -$481.1M | -$491.0M | -$390.8M | -$517.4M | -$462.2M | -$357.9M | -$305.2M | -$259.8M | -$189.3M | -$157.6M | -$133.0M | |||
| Property Plant And Equipment Net | $12.7M | $13.9M | $16.2M | $18.2M | $20.0M | $20.8M | $23.1M | $24.3M | $25.0M | $26.3M | $26.0M | $26.2M | $27.9M | $28.7M | $29.5M | $30.6M | $31.5M | $32.7M | $33.9M | $32.0M | $21.7M | |||
| Prepaid Expense And Other Assets Current | $9.3M | $11.9M | $12.1M | $12.2M | $16.4M | $19.3M | $13.8M | $10.1M | $12.0M | $10.2M | $9.4M | $9.5M | $8.6M | $9.8M | $12.0M | $8.3M | $6.4M | $7.7M | $4.0M | $3.7M | $5.5M | |||
| Other Liabilities Noncurrent | $1.4M | $1.4M | $1.4M | $1.2M | $1.2M | $1.4M | $898.0K | $898.0K | $898.0K | $233.0K | $233.0K | $158.0K | $158.0K | $158.0K | $158.0K | $493.0K | $493.0K | $493.0K | $409.0K | $409.0K | $96.0K | |||
| Other Assets Noncurrent | $4.5M | $4.5M | $4.5M | $6.1M | $6.1M | $7.4M | $8.5M | $8.6M | $8.8M | $5.8M | $5.9M | $5.9M | $5.7M | $6.0M | $2.6M | $2.2M | $1.1M | $403.0K | $149.0K | $110.0K | $60.0K | |||
| Liabilities Current | $80.0M | $84.4M | $109.8M | $142.5M | $147.7M | $164.9M | $155.4M | $132.3M | $99.3M | $160.9M | $149.4M | $142.9M | $132.8M | $74.4M | $64.1M | $71.1M | $65.9M | $71.8M | $58.7M | $67.1M | $55.8M | |||
| Liabilities And Stockholders Equity | $335.3M | $356.4M | $408.3M | $516.0M | $570.7M | $635.5M | $672.4M | $708.7M | $748.3M | $837.0M | $889.7M | $954.5M | $854.2M | $397.1M | $440.4M | $531.6M | $572.0M | $618.9M | $449.7M | $477.3M | $496.0M | |||
| Liabilities | $277.6M | $285.2M | $313.7M | $397.1M | $420.2M | $456.6M | $509.8M | $512.4M | $565.3M | $583.9M | $601.2M | $686.9M | $518.3M | $212.6M | $212.5M | $221.4M | $216.7M | $227.2M | $231.1M | $231.5M | $229.9M | |||
| Contract With Customer Liability Noncurrent | $167.3M | $168.9M | $170.3M | $192.8M | $199.6M | $204.6M | $229.8M | $245.3M | $431.1M | $386.4M | $413.9M | $505.1M | $344.5M | $96.2M | $105.5M | $110.6M | $110.3M | $114.1M | $129.9M | $121.2M | $130.5M | |||
| Contract With Customer Liability Current | $11.7M | $13.4M | $21.9M | $55.4M | $64.0M | $73.4M | $80.6M | $68.6M | $61.8M | $119.7M | $107.0M | $95.6M | $94.7M | $25.4M | $22.7M | $26.6M | $32.7M | $32.1M | $29.5M | $40.9M | $38.5M | |||
| Common Stock Value | $10.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | $7.0K | |||
| Assets Current | $300.4M | $319.2M | $366.7M | $469.4M | $519.7M | $581.4M | $613.1M | $648.0M | $686.0M | $775.0M | $827.0M | $890.9M | $788.0M | $329.3M | $374.7M | $470.0M | $510.1M | $556.2M | $385.5M | $414.6M | $442.1M | |||
| Assets | $335.3M | $356.4M | $408.3M | $516.0M | $570.7M | $635.5M | $672.4M | $708.7M | $748.3M | $837.0M | $889.7M | $954.5M | $854.2M | $397.1M | $440.4M | $531.6M | $572.0M | $618.9M | $449.7M | $477.3M | $496.0M | |||
| Accrued Liabilities Current | $18.3M | $14.2M | $17.3M | $25.7M | $23.1M | $19.4M | $30.4M | $22.9M | $18.6M | $23.2M | $23.7M | $20.0M | $20.6M | $22.1M | $19.0M | $27.1M | $15.6M | $16.7M | $16.5M | $14.6M | $8.0M | |||
| Accrued Clinical Supply Cost | $3.5M | $5.2M | $5.8M | $3.4M | $2.7M | $5.9M | $7.4M | $6.5M | $7.7M | $5.4M | $6.1M | $12.6M | $7.4M | $7.2M | $9.4M | $9.3M | $6.1M | $12.3M | $6.4M | $6.0M | $3.7M | |||
| Accounts Payable Current | $4.8M | $2.2M | $2.3M | $5.0M | $4.4M | $4.6M | $4.7M | $4.7M | $3.1M | $4.5M | $4.6M | $6.8M | $2.3M | $11.9M | $5.3M | $1.4M | $4.8M | $4.0M | $258.0K | $540.0K | $1.2M | |||
| Marketable Securities Current | $214.6M | $262.5M | $316.6M | $420.0M | $455.8M | $489.5M | $486.9M | $498.5M | $473.8M | $574.1M | $636.6M | $414.0M | $261.3M | $193.9M | $252.0M | $376.7M | $411.1M | $387.6M | $294.5M | $341.7M | $375.6M | |||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $197.0K | $96.0K | $191.0K | $931.0K | -$620.0K | -$403.0K | -$721.0K | -$1.4M | -$2.2M | -$6.7M | -$6.2M | -$3.9M | -$41.0K | $203.0K | $410.0K | $1.1M | $1.8M | $2.8M | $226.0K | $441.0K | $108.0K | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $5.0M | -$2.0M | $41.2M | $125.5M | $60.7M | $71.3M | -$4.5M | |||||||||||||||||
| Operating Lease Right Of Use Asset | $15.9M | $17.0M | $19.1M | $20.8M | $23.4M | $24.3M | $26.0M | $26.3M | $27.1M | $28.5M | $29.2M | $29.9M | $31.1M | $31.6M | $32.1M | $27.3M | $27.9M | $28.2M | $28.8M | $29.1M | $30.7M | |||
| Operating Lease Liability Noncurrent | $19.3M | $21.0M | $22.8M | $26.0M | $27.5M | $29.0M | $31.8M | $32.7M | $34.1M | $36.5M | $37.6M | $38.8M | $40.8M | $41.8M | $42.8M | $39.3M | $40.0M | $40.8M | $42.1M | $42.8M | $43.4M | |||
| Operating Lease Liability Current | $9.0M | $8.9M | $8.8M | $8.7M | $8.6M | $8.5M | $8.4M | $8.2M | $8.1M | $8.0M | $7.9M | $7.9M | $7.8M | $7.8M | $7.7M | $6.7M | $6.7M | $6.6M | $6.0M | $5.1M | $4.4M | |||
| Gain Loss On Sale Of Property Plant Equipment | -$9.0K | -$76.0K | ||||||||||||||||||||||
| Issuance Costs Of Common Stock | $300.0K | $3.9M | $1.1M | $3.9M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Share Based Compensation | $26.7M | $39.5M | $42.8M | $46.1M | $40.8M | $30.5M | $16.3M | $6.9M | $5.4M |
| Payments To Acquire Property Plant And Equipment | $41.0K | $1.3M | $2.4M | $4.1M | $3.2M | $5.0M | $15.3M | $1.9M | $801.0K |
| Net Cash Provided By Used In Operating Activities | -$184.0M | -$229.9M | -$184.2M | -$20.3M | $298.6M | -$166.7M | -$99.3M | $127.5M | -$17.8M |
| Net Cash Provided By Used In Investing Activities | $196.6M | $107.1M | $101.9M | -$159.0M | -$49.7M | -$105.1M | -$48.9M | -$224.1M | -$801.0K |
| Net Cash Provided By Used In Financing Activities | $20.2M | $81.5M | $2.6M | $4.5M | $30.3M | $232.1M | $172.4M | $131.1M | -$15.0K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$992.0K | -$5.5M | $5.9M | $3.9M | -$1.1M | $3.8M | $1.6M | $2.2M | $170.0K |
| Increase Decrease In Accrued Liabilities And Accrued Clinical Supply Costs | -$12.9M | $340.0K | $2.5M | -$2.7M | $2.4M | $12.2M | $9.2M | $4.7M | $6.7M |
| Increase Decrease In Accounts Payable | -$524.0K | -$1.4M | -$377.0K | -$572.0K | $1.9M | $2.4M | $152.0K | -$809.0K | -$41.0K |
| Increase Decrease In Contract With Customer Liability | -$21.0M | -$100.6M | -$66.8M | $66.4M | $292.9M | -$21.1M | -$21.2M | $172.5M | $2.1M |
| Increase Decrease In Other Operating Assets | -$4.2M | -$2.9M | $1.0M | $835.0K | $3.0M | $2.5M | $42.0K | -$106.0K | |
| Proceeds From Sale And Maturity Of Marketable Securities | $465.5M | $573.6M | $652.5M | $402.0M | $286.3M | $406.8M | $496.0M | $250.0M | |
| Payments To Acquire Marketable Securities | $271.9M | $467.7M | $551.7M | $556.9M | $343.4M | $506.8M | $529.6M | $472.2M | |
| Increase Decrease In Lease Liabilities | -$6.6M | -$5.8M | -$5.0M | -$4.3M | -$4.0M | -$2.4M | $868.0K | ||
| Proceeds From Stock Options Exercised | $15.0K | $0.00 | $1.1M | $3.1M | $28.5M | $6.3M | $1.5M | ||
| Increase Decrease In Other Noncurrent Liabilities | $503.0K | -$139.0K | $614.0K | $601.0K | -$314.0K | -$21.0K | $353.0K | $75.0K | $14.0K |
| Proceeds From Stock Plans | $217.0K | $1.0M | $1.5M | $1.5M | $1.8M | $1.2M | $798.0K | ||
| Increase Decrease In Collaboration Receivable | $0.00 | -$2.6M | -$4.8M | $7.4M | $0.00 | $0.00 | |||
| Proceeds From Sale Of Available For Sale Securities Debt | $3.0M | $2.6M | $3.5M | $0.00 | $10.7M | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q3 2021 | Q1 2021 | Q3 2020 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Share Based Compensation | $8.4M | $10.3M | $11.0M | $11.9M | $8.8M | $6.6M | $3.2M | $1.1M | ||
| Payments To Acquire Property Plant And Equipment | $20.0K | $533.0K | $1.0M | $692.0K | $947.0K | $3.6M | $2.0M | $613.0K | ||
| Net Cash Provided By Used In Operating Activities | -$60.8M | -$61.3M | -$48.5M | $135.1M | -$52.7M | -$32.3M | -$23.6M | $184.5M | ||
| Net Cash Provided By Used In Investing Activities | $65.7M | -$11.8M | $88.7M | -$12.1M | $109.6M | -$124.9M | -$151.3M | -$179.5M | ||
| Net Cash Provided By Used In Financing Activities | $0.00 | $71.1M | $1.1M | $2.5M | $3.9M | $228.5M | $170.3M | -$62.0K | ||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $679.0K | $2.4M | $977.0K | $2.5M | $3.8M | $3.3M | $2.8M | $1.1M | ||
| Increase Decrease In Accrued Liabilities And Accrued Clinical Supply Costs | -$12.7M | -$10.3M | -$7.0M | -$3.4M | -$5.5M | $7.8M | -$952.0K | -$1.6M | ||
| Increase Decrease In Accounts Payable | $111.0K | $918.0K | -$914.0K | $2.0M | $2.6M | $3.1M | $683.0K | -$783.0K | ||
| Increase Decrease In Contract With Customer Liability | -$3.7M | -$15.9M | $1.3M | $175.5M | -$4.1M | -$7.2M | -$5.6M | $195.2M | ||
| Increase Decrease In Other Operating Assets | -$26.0K | -$16.0K | $2.4M | $358.0K | -$25.0K | $284.0K | -$17.0K | $0.00 | ||
| Proceeds From Sale And Maturity Of Marketable Securities | $121.5M | $185.2M | $210.0M | $18.7M | $110.5M | $81.6M | $118.0M | $0.00 | ||
| Payments To Acquire Marketable Securities | $55.8M | $196.5M | $120.3M | $30.1M | $0.00 | $202.9M | $267.2M | $178.9M | ||
| Increase Decrease In Lease Liabilities | -$1.6M | -$1.4M | -$1.1M | -$995.0K | -$821.0K | -$628.0K | $656.0K | |||
| Proceeds From Stock Options Exercised | $0.00 | $1.1M | $2.5M | $3.9M | $3.2M | $5.0K | ||||
| Increase Decrease In Other Noncurrent Liabilities | $160.0K | $0.00 | $139.0K | $0.00 | -$314.0K | |||||
| Proceeds From Stock Plans | ||||||||||
| Increase Decrease In Collaboration Receivable | $0.00 | $2.1M | $5.4M | $0.00 | ||||||
| Proceeds From Sale Of Available For Sale Securities Debt | $10.7M | $0.00 |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$1.39 | -$1.23 | -$1.56 | -$1.62 | -$0.45 | -$2.45 | -$1.71 | -$4.62 | -$3.55 |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Authorized | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 65.0M | |
| Common Stock Shares Outstanding | 110.4M | 99.1M | 84.9M | 82.9M | 82.0M | 79.3M | 69.1M | 13.8M | |
| Common Stock Shares Issued | 110.4M | 99.1M | 84.9M | 82.9M | 82.9M | 82.0M | 69.1M | 13.8M | |
| Weighted Average Number Of Shares Outstanding Basic | 103.0M | 96.6M | 83.7M | 82.5M | 80.4M | 77.8M | |||
| Weighted Average Number Of Diluted Shares Outstanding | 103.0M | 96.6M | 83.7M | 82.5M | 80.4M | 77.8M | |||
| Earnings Per Share Basic | $-1.39 | $-1.23 | $-1.56 | $-1.62 | $-0.45 | $-2.45 | |||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 80.4M | 77.8M | 61.7M | 11.3M | 9.1M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 | Q2 2019 | Q1 2019 | Q4 2018 | Q3 2018 | Q2 2018 | Q1 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.34 | -$0.30 | -$0.41 | -$0.43 | -$0.40 | -$0.38 | -$0.53 | $0.02 | -$0.55 | -$0.56 | $0.12 | -$0.54 | $1.49 | -$0.69 | -$0.66 | -$0.67 | -$0.58 | -$0.53 | -$0.45 | -$0.47 | -$0.36 | -$0.42 | -$1.48 | -$1.34 | -$1.00 | -$0.78 |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| Common Stock Shares Authorized | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | |||||
| Common Stock Shares Outstanding | 107.4M | 101.2M | 100.0M | 97.9M | 97.3M | 96.4M | 84.1M | 83.8M | 83.4M | 82.0M | 82.0M | 82.0M | 79.3M | 80.0M | 79.7M | 79.3M | 79.0M | 68.9M | 68.8M | 68.9M | ||||||
| Common Stock Shares Issued | 107.4M | 101.2M | 100.0M | 97.9M | 97.3M | 96.4M | 84.1M | 83.8M | 83.4M | 82.7M | 82.5M | 82.3M | 81.2M | 80.0M | 79.7M | 79.3M | 79.0M | 68.9M | 68.8M | 68.9M | ||||||
| Weighted Average Number Of Shares Outstanding Basic | 102.6M | 100.4M | 99.4M | 97.5M | 96.7M | 93.8M | 83.9M | 83.5M | 83.1M | 82.6M | 82.4M | 82.1M | 81.0M | 79.8M | 78.8M | |||||||||||
| Weighted Average Number Of Diluted Shares Outstanding | 102.6M | 100.4M | 99.4M | 97.5M | 96.7M | 93.8M | 83.9M | 83.6M | 83.1M | 82.6M | 82.6M | 82.1M | 85.2M | 79.8M | 78.8M | |||||||||||
| Earnings Per Share Basic | $-0.34 | $-0.30 | $-0.41 | $-0.43 | $-0.40 | $-0.38 | $-0.53 | $0.02 | $-0.55 | $-0.56 | $0.12 | $-0.54 | $1.56 | $-0.69 | $-0.67 | |||||||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 82.1M | 79.4M | 78.8M | 78.4M | 74.8M | 67.6M | 67.3M | 43.8M | 11.4M | 11.2M | 10.9M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $26.7M | $39.5M | $42.8M | $46.1M | $40.8M | $30.5M | $16.3M | $6.9M | $5.4M |
| Stock Issued During Period Value Stock Options Exercised | $15.0K | $1.1M | $3.1M | $28.5M | $6.3M | $1.5M | |||
| Depreciation And Amortization | $5.7M | $5.4M | $5.7M | $5.7M | $6.3M | $5.9M | $3.8M | $1.0M | $680.0K |
| Capital Expenditures Incurred But Not Yet Paid | $0.00 | $172.0K | $493.0K | $705.0K | $428.0K | $3.5M | $293.0K | $353.0K | |
| Additional Paid In Capital | $1.00B | $955.7M | $844.0M | $798.7M | $748.0M | $677.0M | $414.4M | $17.1M | |
| Amortization Right Of Use Asset | $3.9M | $3.4M | $3.1M | $2.8M | $2.0M | $1.4M | $1.8M | ||
| Stock Issued During Period Value Employee Stock Purchase Plan | $217.0K | $1.0M | $1.5M | $1.5M | $1.8M | $1.2M | $798.0K | ||
| Stock Issued During Period Value New Issues | $20.0M | $71.1M | $224.5M | $168.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q3 2018 | Q2 2018 | Q1 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $6.4M | $7.1M | $8.4M | $9.0M | $9.9M | $10.3M | $10.1M | $10.2M | $11.0M | $10.8M | $12.5M | $11.9M | $10.2M | $9.1M | $8.8M | $8.0M | $6.9M | $6.6M | $4.1M | $3.7M | $3.2M | $2.0M | $1.2M | $1.1M |
| Stock Issued During Period Value Stock Options Exercised | $1.1M | $489.0K | $41.0K | $2.5M | $14.8M | $2.0M | $3.9M | $286.0K | $2.2M | $3.2M | $720.0K | $63.0K | $5.0K | |||||||||||
| Depreciation And Amortization | $984.0K | $1.4M | $1.4M | $1.6M | $1.5M | $1.4M | $298.0K | $212.0K | ||||||||||||||||
| Capital Expenditures Incurred But Not Yet Paid | $0.00 | $31.0K | $305.0K | $499.0K | $628.0K | $178.0K | $1.1M | $109.0K | ||||||||||||||||
| Additional Paid In Capital | $992.3M | $971.2M | $964.0M | $945.0M | $936.0M | $925.5M | $831.9M | $821.9M | $810.8M | $787.1M | $775.8M | $762.5M | $726.7M | $701.7M | $689.6M | $667.0M | $658.6M | $648.8M | $407.6M | $402.8M | $399.1M | |||
| Amortization Right Of Use Asset | $864.0K | $848.0K | $742.0K | $670.0K | $461.0K | $297.0K | $768.0K | |||||||||||||||||
| Stock Issued During Period Value Employee Stock Purchase Plan | $122.0K | $644.0K | $881.0K | $866.0K | $969.0K | $715.0K | ||||||||||||||||||
| Stock Issued During Period Value New Issues | $14.7M | $71.1M | $224.5M | $168.2M |
Most recent annual filing with the SEC: February 25, 2026
Data sourced from SEC EDGAR public filings as of August 4, 2026.